and hepatocytes 2 . In the kidney, CD36 is expressed in the proximal 10 and distal tubular epithelium 11 , and on podocytes 12 , mesangial cells 13, 14 , microvascular endothelial cells and interstitial macrophages 15, 16 . Renal CD36 expression is upregulated by hyperlipidaemia and hyperglycaemia, and patients with chronic kidney disease (CKD), particularly those with diabetic nephropathy, show increased expression of the protein 12, 17 . CD36 has multiple ligands, which can be classified as lipid-related ligands, such as (long-chain) fatty acids 18 , oxidized LDL (ox-LDL) 19, 20 , and oxidized phospho lipids 21 ; and as protein-related ligands, including advanced oxidation protein products (AOPPs) 22 , advanced glycation end products (AGEs) 23 , thrombo spondin -1 (TSP1), TSP2 (REFS 24, 25) , S100 family proteins (S100-A8, S100-A9 (REF. 26 ) and S100-A12 (REF. 27 )), amyloid proteins 28, 29 , and the synthetic growthhormone-releasing peptide family members hexarelin 30 and EP 80317 (REF. 31 ). Apoptotic cells can also act as ligands for CD36 (REF. 32) (TABLE 1) . Many of these ligands have important roles in kidney injury.
The findings of several studies suggest that CD36 serves as a signalling hub for lipid homeostasis 33, 34 , immunological responses 35 , and programming of energy availability 36, 37 . CD36 also mediates crosstalk between different cell types -for example between macrophages and endothelial cells or between tubular cells and macrophages or myofibroblasts -in response to oxidized ligands such as ox-LDL, oxidized phospholipids, apoptotic cells and AOPPs 38 . In proximal tubular epithelial cells (PTECs), CD36 is involved in regulating energy levels through mitochondrial β-oxidation of fatty acids, which are a major source of renal ATP production 39 . Disruption of any of the above mentioned CD36-dependent pathways can modulate the develop ment of kidney fibrosis 40 . In mice, blocking CD36 prevents CKD progression 41 , demonstrating an important role for CD36 in renal injury and its potential as a therapeutic target. In this Review, we focus on the biological, physiological, and pathological roles of CD36 that might promote CKD progression: namely, roles in lipid homeostasis, metabolic inflammation, apoptosis, and reprogramming of energy metabolism. We also discuss the potential of CD36 as a therapeutic target for kidney disease. The CD36 gene The human CD36 gene is ~46 kb long and is located on chromosome 7q11.2. The gene has 15 exons; exons 4-13 and part of exons 3 and 14 encode the CD36 protein 42 . Mutations in the CD36 gene are linked to abnormalities in plasma fatty acids and triglycerides, which are risk factors for metabolic diseases involving insulin resistance 43 .
Transcriptional regulation
The CD36 gene promoter contains CCAAT/enhancerbinding protein (C/EBP) responsive elements, which enable C/EBP to bind and regulate CD36 expression in various cell types 7 . Nuclear receptors also have important roles in the transcription of the CD36 gene. For example, peroxisome proliferator-activated receptor α (PPARα) and PPARγ regulate CD36 expression in human macrophages 44 and cardiac microvascular endothelial cells 45 . In addition, high glucose levels activated a PPARγ-dependent pathway that led to increased CD36 expression in the human HK-2 proximal tubular cell line 46, 47 . Studies suggest that the CD36 promoter contains a PPAR-responsive element 44, 45 ; binding of PPAR to this element might regulate CD36 expression.
Response element binding sites for the pregnane X receptor (PXR) and liver X receptor (LXR) have also been identified in the CD36 promoter, and activation of these receptors upregulated CD36 expression and promoted hepatic steatosis in mice 33 . In models of diabetic kidney disease, LXR activation had renoprotective effects [48] [49] [50] . The reported mechanisms were independent of CD36, but the levels of this protein were not examined in all studies.
Lipids, including fatty acids 12 and ox-LDL 51 , can upregu late CD36 gene expression. Following CD36-mediated uptake in macrophages, ox-LDL is metabolized to produce 9-hydroxyoctadecadienoic acid and 13-octadecadienoic acid. These metabolites are PPAR agonists that activate PPAR through protein kinase C (PKC), protein kinase B and p38 mitogen-activated protein kinase (MAPK) pathways. Following their activation, PPAR and retinoid X receptor form a heterodimer that binds to the CD36 promoter and increases CD36 transcription 52 . In turn, increased expression of CD36 leads to an increase in ox-LDL uptake in macrophages and promotes foam cell formation 53 . In contrast to ox-LDL, oxidized HDL (ox-HDL) inhibits macrophage CD36 expression via PPAR-dependent mechanisms 54 . Lysophosphatidic acid (LPA) is a central component of cellular phospholipid metabolism and an important regulator of vascular remodelling and inflammation 55 . LPA downregulates CD36 transcription in microvascular endothelial cells via a protein kinase D1 (PKD1)-dependent pathway 56 . LPA/PKD1-induced downregulation of CD36 in these cells is mediated by nuclear accumulation of histone deacetylase 7, which interacts with forkhead box protein O1 to suppress CD36 transcription 57 . In microvascular endothelial cells, LPA/PKD1 signalling activated a transcriptional pro angio genic switch involving ephrin B2, which is a critical mediator of angiogenesis and arteriogenesis 57 . In addition to lipids, high glucose levels and insulin have been reported to induce the expression of CD36 in mesangial cells 58 and cardiac myocytes 59 , respectively. Monocyte-colony stimulating factor 60 , phorbol ester 61 , tumour necrosis factor (TNF) 62 , IL-4 (REF. 63 ) and thiazolidinediones 64, 65 can also promote CD36 expression in monocytes and macrophages. By contrast, lipopolysaccha ride 66 , dexamethasone 60 , interferon 67 , transforming growth factor (TGF)-β1/2 (REF. 68 ), tamoxifen 69 , and HDL 70 inhibit macrophage CD36 expression, whereas statin treatment has been reported to substantially reduce platelet CD36 expression 71 .
The CD36 protein Full-length human CD36 comprises around 472 amino acids and has a predicted molecular mass of 53 kDa 72 . The protein has two transmembrane domains with a huge extracellular region, which contains the ligand-binding region, and two short cytoplasmic tails at the N-terminus and C-terminus 42, 73 . The extracellular loop contains a large hydrophobic cavity that traverses the entire length of the molecule. This cavity is thought to serve as a tunnel through which hydrophobic ligands (including cholesterol and fatty acids) are delivered from the extracellular space to the outer leaflet of the plasma membrane 74 (FIG. 1) .
CD36 also has a positively charged domain (containing a lysine cluster) that binds negatively charged ligands 75 . Almost all end-stage biological oxidation products are negatively charged, including ox-LDL, AOPPs, AGEs, and apoptotic cells. Binding of these ligands, which are markers of cellular oxidative stress and the denaturation of lipids or proteins, to CD36 triggers pathophysiological responses such as inflammatory and proatherogenic processes 15, 23, 53 . CD36 has been shown to interact with TSP1 through electrostatic forces mediated by the multiple negatively charged CD36, LIMP-2, Emp sequence homology domain (CLESH) residues of CD36 and the positively charged surface of the thrombospondin type I repeat 2 domain of TSP1 (REF. 76 ). This interaction is required for the CD36 CLESH-dependent antiangiogenic activity of TSP1. In addition to transmembrane CD36, a circulating form of CD36, known as soluble CD36 (sCD36), exists. Studies have suggested that sCD36 consists of part of the extracellular segment of CD36 (REFS 77, 78) . The huge CD36 extracellular segment might undergo a cut-down process by a plasma protease, resulting in release of sCD36 into the circulation 78 . ADAM17 has been shown to mediate proteolytic cleavage of the CD36 extracellular domain, which might be a mechanism to regulate efferocytosis or clearance of apoptotic cells 79 . Another study has reported, however, that rather than being a soluble, cut-down product of the CD36 extracellular domain, sCD36 is associated with a specific subset of circulating microparticles 80 . Thus, further studies are required to clarify the mechanism by which sCD36 is formed.
Post-translational modifications
Post-translational modifications might have an important role in regulating CD36 location and function. In general, glycosylation, ubiquitylation, and palmitoylation are involved in regulating CD36 stability, protein folding, and trafficking, whereas phosphorylation at extracellular sites affects the rate of ligand (such as fatty acid) uptake 81 . Acetylation of CD36 has also been reported 82, 83 , but the effects of this modification on CD36 expression and function have not yet been elucidated.
Phosphorylation. CD36 has two phosphorylation sites at Thr92 and Ser237, both of which modulate ligand binding within the extracellular loop. The Thr92 site is a putative PKC binding site, whereas the Ser237 site is recognized by PKA 84, 85 . Phosphorylation of these sites is positively linked to CD36 function, possibly through the modulation of ligand binding.
In platelets, phosphorylation and dephosphorylation of CD36 on the cell membrane affects TSP binding and controls collagen adhesion 85 . In cell-free conditions, phosphorylation of CD36 at Thr92 dose-dependently correlated with inhibition of TSP binding 86 . In a melanoma cell line, phosphorylation of CD36 at Thr92 was shown to occur during protein synthesis and trafficking through the Golgi 86 . Phosphorylation of CD36 at Thr92 is necessary for binding of CD36 to erythrocytes that are infected by Plasmodium falciparum 87 . Phosphorylation of CD36 at Ser237 has been reported to inhibit fatty acid uptake in platelets and enterocytes 88, 89 . Whether such CD36 phosphorylation also leads to inhibition of fatty acid uptake in the kidney has not yet been investigated.
Glycosylation.
The process of glycosylation occurs within the endoplasmic reticulum (ER) and the Golgi, where it provides stable coupling of complex oligosaccharide structures to proteins 90 . The majority of glycosylation is N-linked at asparagine residues 91 . CD36 has 10 potential glycosylation sites, all of which are located within the extracellular loop, and fully glycosylated CD36 is an approximately 88 kDa transmembrane glyco protein receptor 72 . Glycosylation of CD36 is a hydrophilic modification, which is very important for protein folding, stability, and trafficking, but does not affect ligand binding 91 . In intestinal enterocytes, enhanced CD36 glycosylation reportedly results in an increase in the absorption of fatty acids by unknown mechanisms 9 . AGEs, advanced glycation end-products; AOPPs, advanced oxidation protein products; ox-HDL, oxidized high density lipoprotein; ox-LDL, oxidized low density lipoprotein; ROS, reactive oxygen species.
In spontaneously hypertensive (SHR) rats, CD36 is mutated at multiple sites including Asp102, which is located within the fatty acid binding pocket and is a potential N-glycosylation site 92 . In the hearts of these rats, both total CD36 protein expression and fatty acid utilization were significantly reduced, perhaps owing to a decrease in CD36 stability as a result of the mutation at Asp102 (REF. 92 ). Further studies are needed to investigate the role of glycosylation in altered fatty acid uptake in CKD.
Palmitoylation. Palmitoylation regulates the subcellular localization, membrane interactions, and subcellular trafficking of proteins. CD36 has four palmitoylation sites, which are located in the third, seventh, 464th and 466th cysteine residues in the cytoplasmic segment of the N-terminal and C-terminal 93 . Palmitoylation of CD36 is a reversible catalytic process. In most cases the reversible covalent bond occurs between palmitate and cysteine residues via a thioester linkage. Protein palmitoylation requires palmitoyl-transferases (PATs) and palmitoyl-protein thioesterases (PPTs) for palmitoylation and depalmitoylation, respectively 94 . Under palmitic acid stimulation, PATs cause CD36 palmitoylation in the ER 93, 95 .
Palmitoylated CD36 is located in the lipid rafts of the cell membrane where it mediates the adsorption and transport of fatty acids 96 . Inhibition of palmitoylation stops the maturation of CD36 and causes CD36 precursor proteins to remain in the ER; these proteins undergo ubiquitylation and degradation so have a short half-life 95 . Inhibition of CD36 palmitoylation might, therefore, be a potential strategy to reduce CD36-mediated lipid accumulation and inflammatory signalling; however, whether such palmitoylation occurs in renal cells has not been determined.
Ubiquitylation. The polyubiquitylation pathway targets proteins for proteasomal degradation. CD36 has two ubiquitylation sites in the C-terminus at Lys469 and Lys472 that are responsible for its regulation by polyubiquitylation 97 . In a mouse muscle cell line (C2C12), oleic acid increased the polyubiquitylation of CD36 and decreased cellular fatty acid uptake, whereas insulin had the opposite effect 97 . The degree of polyubiquitylation did not affect the relative distribution of CD36 between the intracellular storage compartments and the cell surface, but was inversely associated with total CD36 protein expression 97 . Platelet-derived exosomes also increase the polyubiquitylation of CD36 and enhance its proteasomal degradation 98 . In contrast to polyubiquitylation, monoubiquitylation is considered to be non-degradative and has other functions such as protein complex formation. The intracellular C-terminal lysines in CD36 can be targeted by parkin, which has E3 ubiquitin-protein ligase activity and parti cipates in the process of protein monoubiquitylation 99 . In mice, a high-fat diet increased hepatic parkin and CD36 levels, which contributed to increased lipid accumulation and insulin resistance 100 . Parkin-knockout mice on a high-fat diet had reduced hepatic CD36 levels that blunted the maladaptive response to lipid metabolism and insulin signalling compared with controls.
As parkin also has polyubiquitylation activity 101 , its downstream effects can be both dependent and independent of the proteasome. The function of parkin might vary between different tissues and conditions such that it operates as a monoubiquitinase in some settings and as a polyubiquitinase in others. The role of fatty acids in CD36 degradation in the kidney remains unclear.
Acetylation. Protein acetylation has roles in apoptosis 102 , subcellular protein localization 103 , glucose and fatty acid metabolism 82 , DNA and protein interactions, DNA replication, repair and transcriptional activity, and protein stability 104 . Acetylation of CD36 at Lys52, Lys166, Lys231 and Lys403 has been shown using mass spectrometry 82, 83 , but the biological effects of this acetylation remain unclear.
Cellular location
CD36 is not only present at the cell surface but also in endosomes, the ER and mitochondria 105 . The protein can migrate between these locations via vesicular transport along exocytotic and endocytic pathways to control lipid homeostasis and energy reprogramming 2,59,106-108 . Motif for dimerization A net translocation of CD36 to the plasma membrane is induced by several physiological stimuli, most notably elevated circulating insulin levels 106 and muscle contraction 109 . Insulin-induced CD36 translocation requires activation of the phosphatidylinositol 3-kinase-Akt2 signalling axis 59, 106 , whereas muscle-contraction-induced CD36 translocation is dependent on activation of AMPactivated kinase (AMPK) 109, 110 . Inflammation increases CD36 transcription, translation, and translocation to the cell surface 96 . Post-translational modifications could be major factors that determine the cellular location and function of CD36.
High molecular weight CD36 homodimers and oligomers have been detected in human platelets and in a primate renal fibroblast cell line (COS-7 cells) transfected with human CD36 (REFS 24, 111) . G12xxxG16xxxA20 and A20xxG23 motifs in the N-terminal transmembrane domain of CD36 are responsible for its dimerization 112 .
Whether homodimerization of CD36 and palmitoylation of cysteine residues close to the N-terminal region affect CD36 function, cellular location, ligand binding and signal transduction remains unclear.
Roles of CD36 in renal pathophysiology CD36 modulates multiple pathways that have important roles in acute kidney injury (AKI) and CKD.
Fatty acid accumulation
The lipid nephrotoxicity hypothesis, which was first proposed by Moorhead et al. in 1982 (REF. 113 ) and updated by Ruan et al. in 2009 (REF. 114 ), suggests that dyslipidaemia promotes the progression of CKD by causing inflammatory, oxidative and ER stress. This concept has led to a large number of studies focusing on the relationship between lipids and renal disease. Evidence from experimental animals and from humans suggests a direct role of lipids, including non-esterified fatty acids (NEFAs), triacylglycerols and cholesterol, in the initiation and progression of CKD 115 . The total lipid content of the healthy human kidney is estimated to comprise approximately 3% of the wet weight 116 . More than half of this lipid content is phospholipids, approximately one-fifth is triglycerides, and about one-tenth is NEFAs 117 . In vivo studies using radiolabelled fatty acids in dogs 118 , as well as analysis of differences in the levels of substrates, including fatty acids, lactate, citrate and pyruvate, between human arterial and renal venous blood 116 , have indicated that the kidney extracts fatty acids from the circulation, and that fatty acid oxidation (FAO) could account for more than half of renal oxygen consumption. Importantly, fatty acid extraction by the human kidney in vivo was linearly dependent on plasma fatty acid concentrations 116 . Kidney uptake of circulating fatty acids may require dissociation from albumin, which is mediated by specific membrane proteins such as CD36 (REF. 119 ). The renal proximal tubule retrieves albumin-bound fatty acids from the filtrate by CD36-mediated or receptormediated albumin endocytosis 120 . In mice, the kidney takes up NEFAs and increases FAO during fasting states, whereas de novo lipid synthesis pathways are downregulated 121 . Similar to the liver and in contrast to muscle, CD36 and lipoprotein lipase are not required for the uptake of NEFAs in the normal murine kidney during fasting 121 . As passive transmembrane movement of fatty acids might be an important mode of fatty acid uptake during fasting, these findings do not rule out a role of CD36 in fatty acid transport in the kidney.
Fatty acids are the preferred energy source for PTECs; therefore, a reduction in FAO in CKD affects kidney lipid metabolism by disrupting the balance between fatty acid synthesis, uptake and consumption 40 . The outcome is intracellular lipid accumulation, which has an important role in the pathogenesis of kidney fibrosis 40 .
In the settings of murine and human CKD, genes that are associated with FAO are downregulated in the kidney 40 . Kidney biopsy samples from patients with diabetic nephropathy show lipid accumulation in the glomeruli and tubulointerstitium together with upregulation of CD36 compared to normal control samples 12, 17 . In mice, transgenic overexpression of tubular CD36 led to an increase in intrarenal lipid accumulation but only a slight increase in the expression of profibrotic genes in the absence of kidney injury 40 . In podocytes, CD36-dependent uptake of palmitic acid led to a dose-dependent increase in the levels of mitochondrial reactive oxygen species (ROS), depolarization of mitochondria, ATP depletion, and apoptosis 12, 28 . Moreover, studies in mouse models have shown that in the setting of CKD, CD36 promotes fibrogenesis by increasing oxidative stress and activating pro-inflammatory pathways, although the role of CD36 in FAO was not investigated 122 .
Further research is required to identify the differential roles of passive and active fatty acid transport in kidney disease as well as the major receptors that are involved in fatty acid uptake in the kidney. Such studies will enable greater insight into the mechanisms of fatty acid metabolic dysfunction in kidney disease.
Interactions with oxidized lipids
Accumulation of ox-LDL in the circulation and renal interstitium has been reported in experimental models and in patients with CKD or end-stage renal disease (ESRD) 123, 124 . Macrophage CD36 binds large amounts of ox-LDL and mediates the endocytosis and degradation of ox-LDL in vivo; some studies have reported that CD36 is responsible for more than half of ox-LDL uptake in macrophages 125 . In hypercholesterolaemic mice with kidney injury as a result of unilateral ureteral obstruction (UUO), ox-LDL deposition was evident in the renal tubules and interstitial compartment and correlated with fibrosis 11 . CD36 deficiency in the same model reduced the activation of pro-inflammatory and oxidative pathways, resulting in a substantial reduction in the number of interstitial myofibroblasts compared with wild-type controls 122 . Even in normocholesterolaemic states, however, chronic kidney injury results in the de novo generation of intracellular oxidized lipids in macrophages 125 . In a mouse model, renal fibrosis induced by UUO led to a 2-6-fold increase in levels of the intracellular lipid
Matricellular protein
A dynamically expressed non-structural protein that is present in the extracellular matrix.
peroxides hydroxyoctadecadienoic acid (HODE) and hydroxyeicosatetraenoic acid (HETE) in CD36-positive renal macrophages 125 . The absence of macrophage CD36 expression in this model led to a 50% reduction in intracellular levels of HODE and HETE, reduced fibrosis and preserved kidney function. In this nonproteinuric model of CKD, macrophage CD36 formed a heterodimer with Lyn kinase at its C-terminus to activate a NF-κB p50p65-dependent pro-inflammatory pathway 125 . Activation of NF-κB increases the production of pro-inflammatory cytokines and chemokines, which might trigger an influx of monocytes and an accumulation of macrophages in the kidney 41 . In proximal tubular cells, CD36 heterodimerizes with the Na HDL is susceptible to structural modifications, including oxidation, in the setting of metabolic disorders 127, 128 . Oxidative modification of HDL (ox-HDL) has been reported in patients with ESRD, particularly in those with diabetic nephropathy 129 . The levels of oxidized phospholipids were also significantly increased in apoptotic cells in an experimental CKD model 125 . In human renal tubular (HK-2) and mesangial cells, binding of ox-HDL to CD36 enhanced ROS production and upregulated the expression of pro-inflammatory factors via activation of p38/MAPK, extracellular-regulated kinase (ERK)/MAPK and NF-κB 130 . Src family kinase was also activated and apoptosis was increased in HK-2 cells following stimulation with ox-HDL 130 .
Endocytosis of AOPPs
AOPPs are a family of oxidized, dityrosine-containing, crosslinked protein compounds that are formed by the reaction of plasma proteins with chlorinated oxidants. Studies suggest that AOPPs are important renal pathogenic mediators in the progression of CKD and associated cardiovascular disease 131, 132 . CD36 is a receptor for AOPP-modified albumin in proximal tubular cells 22 . Moreover, in HK-2 cells, anti-CD36 antibody treatment inhibited the endocytic association and degradation of AOPPs that was induced by oxidant-damaged human serum albumin (AOPPs-HSA) 22 . AOPPs-HSA increased intracellular ROS generation and TGF-β1 secretion in these cells, whereas anti-CD36 antibody abrogated AOPPs-HSA-induced upregulation of TGF-β1 (REF. 22 ).
CD36 binding of AOPPs activates the reninangiotensin system in proximal tubular NRK52E cells via PKCα/NADPH-dependent activation of NF-kB 133 . Blocking CD36, PKCα or NADPH oxidase dramatically abolished AOPP-augmented activation of the transcription factor AP-1 and NF-kB in these cells, suggesting that AOPPs activate NF-kB and AP-1 through the CD36-PKCα-NADPH oxidase pathway 133 .
Interactions with thrombospondin 1 TSP1 is a matricellular protein that inhibits angiogenesis and causes apoptosis in vivo and in vitro in several cells and tissues, including renal tubular epithelial cells 134 and podocytes 135 . Interaction of TSP1 with CD36 is critical for activation of latent TGF-β and might be involved in initiating and regulating cellular fibrosis 136 . TSP1 and CD36 are induced early in renal ischaemia-reperfusion injury (IRI) and TSP1-null mice show substantial preservation of kidney function after IRI 137 . In rodent kidneys subjected to IRI, formation of the TSP1-CD36 complex in proximal tubular cells led to cleavage of caspase 3 and apoptosis 137 . Similarly, in an adriamycin-induced nephropathy mouse model of focal segmental glomerulosclerosis, TSP1 expression increased in injured podocytes and led to CD36-dependent apoptosis via activation of the p38MAPK pathway 138 . In a model of diet-induced obesity, podocyte apoptosis and dysfunction were attenuated in TSP1-deficient and in CD36-deficient mice, suggesting that the interaction of TSP1 with CD36 contributes to obesityassociated podocytopathy 135 . Moreover, blocking TSP1 binding to CD36 using peptide treatment attenuated fatty-acid-induced podocyte apoptosis, suggesting that the TSP1/CD36 interaction mediates this process.
The antiangiogenic effects of TSP1 and TSP2 are mediated through binding to microvascular CD36 as evidenced by the finding that TSP1 and TSP2 do not inhibit neoangiogenesis in CD36 −/− mice 139, 140 . LPA has been shown to downregulate CD36 transcription via PKD1 and antagonize the anti angiogenics effect of TSP1 and TSP2 (REF. 56 ).
Endocytosis of AGEs
AGEs are a heterogeneous and complex group of compounds that have an important role in the development of diabetic nephropathy. Using a Chinese hamster ovary cell line that overexpressed CD36, Ohgami et al. made the interesting discovery that AGEs are recognized by CD36, endocytosed in a dose-dependent fashion, and undergo lysosomal degradation 6 . AGE-bovine serum albumin upregulated CD36 expression and lipid uptake in monocytes from patients with diabetes and in aortic vascular smooth muscle cells from diabetic rats [141] [142] [143] . AGE-LDL has been shown to potentially induce production of proinflammatory cytokines by interacting with CD36 in mouse monocytes 144 . Moreover, early work from Susztak and colleagues demonstrated that CD36 expression is necessary and sufficient to mediate apoptosis of PTECs induced by AGEs and fatty acids through sequential activation of Src kinase, p38MAPK and caspase 3 (REF. 10 ).
Amyloid deposition
Deposition of amyloid fibrils derived from serum amyloid A protein (SAA) causes systemic amyloid A (AA) amyloidosis, which is a serious complication of chronic inflammatory conditions. The kidney is one of the organs that is most often affected by AA amyloidosis. Renal AA amyloidosis leads to progressive deterioration of renal function and is considered to be intractable 145 . CD36 is a receptor for SAA 23 and has been reported to have a role in SAA-induced pro-inflammatory activation through JNK and ERK1/2-mediated signalling in the HEK293 human embryonic kidney cell line 108 . This finding suggests that CD36 has an important role in the initiation of inflammatory reactions and oxidative stress in renal AA amyloidosis. Further exploration of the role of CD36 in this disease would, therefore, be of interest.
Other activators of CD36
In HK-2 cells, high glucose levels increased CD36 expression in a time-dependent manner and induced epithelial-to-mesenchymal transition at 72 h 146 . This effect could be prevented either by knockdown of CD36 or by treatment with the CD36 antagonist sulfosuccinimidyloleate 146 . Studies using a proximal tubular cell line (LLC-PK1) showed that albumin uria enhanced the secretion of bioactive TGF-β and fibronectin and upregulated CD36 (REF. 147 ). Treatment with CD36 siRNA abrogated these increases, suggesting potential anti-fibrotic effects.
CD36 signalling and kidney injury
CD36 is able to generate cell-specific responses to multiple ligands through the binding of context-specific binding partners (such as Toll-like receptor 2 (TLR2) 148 , TLR4, TLR6 (REFS 149, 150) , and TGF-β 22 signalling pathways (FIG. 2) . These effects result in meta bolic inflammation, energy reprogramming, apoptosis and fibrosis, which contribute to the development of renal injury.
Fatty acids and ox-LDL increase the apoptosis of human macrophages 19, 155 . In ER-stressed murine macro phages, oxidized phospholipids, ox-LDL, saturated fatty acids, and lipoprotein(a) have been shown to trigger apoptosis via an interaction between CD36 and TLR2/TLR6 heterodimers 21 . When exposed to ox-LDL and amyloid β, CD36 forms heterodimers with TLR4 and TLR6 via its C-terminus Tyr463, and CD36 -Lyn kinase interaction, causing inflammatory responses 150 . The interactions of CD36 with TLR2 (REF. 148 ), tetraspanin 151 and integrins 152, 153 contribute to ox-LDL uptake and foam cell formation in atherosclerosis.
Whether all CD36 ligands have similar effects on binding partners, downstream signal transduction pathways and their biological activity in the kidney is unclear as are the mechanisms by which CD36 senses different ligands and exerts specific responses. The specific effects of crosstalk between CD36 ligands, binding partners and signal pathways on inflammation, apoptosis, and especi ally energy reprogramming in the kidney, warrant further investigation.
Macrophage infiltration into the kidney has an important role in CKD. Increased CD36 expression has been observed in the kidneys and peripheral blood monocytes of patients and mice with CKD 156, 157, 5, 158 . Moreover, in mouse models of UUO and ischaemiareperfusion injury, knockout of CD36 in monocytes decreased the severity of fibrosis and improved kidney function 125 . The role of CD36 in crosstalk between macrophages and kidney cells and in the initiation and amplification of inflammation, apoptosis and fibrosis warrants further investigation.
Energy reprogramming
Mitochondrial β-oxidation of fatty acids is a primary source of renal ATP production, particularly in the proximal tubule, which has a high energy demand and relatively low glycolytic capacity, suggesting that fatty acids are the preferred energy source for proximal tubule cells 39 . A reduction in FAO in CKD would affect lipid metabolism by disrupting the balance between fatty acid synthesis, uptake, and consumption, leading to dysregulated intracellular lipid accumulation, which has a crucial role in the pathogenesis of kidney fibrosis 40 . Metabolic reprogramming is characterized by the decreased expression of key enzymes and regulators of FAO and increased intracellular lipid deposition. Inhibition of FAO in tubular epithelial cells in vitro causes ATP depletion, cell death, de-differentiation, and intracellular lipid deposition 40 . Diabetic complications have been shown to arise in the context of distinct tissue-specific alterations in metabolism 159 . In the diabetic kidney, substrate utilization progressively increased with simultaneous consumption of glucose and fatty acids, suggesting that metabolic reprogramming with enhanced protein acetylation led to mitochondrial dysfunction 159 . Increasing amounts of fatty acid bound to albumin led to defects in mitochondrial respiration and to peroxidemediated apoptosis of tubular cells 160 . Compared to individuals with normal kidney function, patients with CKD had markedly lower transcriptional levels of genes related to fatty acid metabo lism and their key transcriptional regulator complex PPARα-PPARγ co-activator 1-α (PGC-1α) 40 . Moreover, proximal tubular cells with defective FAO showed fibrosis pheno types with ATP depletion, increased cell death, dedifferentiation and intracellular lipid deposition 40 . Thus, restoring meta bolic defects in FAO might be a potential therapeutic strategy for CKD (FIG. 3) .
Mitochondrial transfer of fatty acids is the ratelimiting step in FAO. This transfer requires linking of fatty acid products to carnitine via carnitine palmitoyltransferase 1 (CPT1) and CPT2 (REF. 161 ). The mitochondrial enzyme carnitine O-acetyltransferase (CRAT) complexes excess acyl groups to carnitine, enabling them to exit the mitochondria 162 . The importance of CD36 in FAO is thought to relate to its function in the mitochondrial transfer of fatty acids, as has been demonstrated in human skeletal muscle cells 16, 161 . CD36 was identified in purified mitochondria from these cells and was shown to co-immunoprecipitate with CPT1. In addition, increased mitochondrial CD36 content paralleled the upregulation of FAO in skeletal muscle 16, 161 . CD36 might have a similar function in mitochondrial fatty acid transfer in PTECs, which also have a high energy demand. PTECs express high levels of CPT1A, CPT1B, CPT2 and CRAT 163 . In contrast to CRAT in the liver and skeletal muscle, which can be both mitochondrial and peroxisomal, renal CRAT is almost exclusively mitochondrial 164 . Any alterations in CPT1 activity will likely affect fatty acid metabolism and oxidation in proximal tubular cells. Deletion of CPT1B Nature Reviews | Nephrology Binding of a variety of ligands to CD36 on the plasma membrane initiates the assembly of a complex comprising CD36 and Toll-like receptor 4 (TLR4) and TLR6; TLR2 and TLR6; or Na + /K + -ATPase. This complex activates nuclear factor-κB (NF-κB); the NLRP3 inflammasome; protein kinase C (PKC)-NAPDH oxidase; Scr, Lyn, Fyn and mitogen-activated protein kinases (MAPKs); and transforming growth factor-β (TGF-β)-specific cell signalling pathways. Activation of these pathways has been shown in renal cells (green), renal macrophages (blue) or both cell types (yellow). These processes result in lipid accumulation, metabolic inflammation, apoptosis, energy metabolism reprogramming and renal fibrosis. ACE, angiotensinconverting enzyme; AGEs, advanced glycation end-products; AGT, angiotensinogen; Ang ll, angiotensin ll; AOPPs, advanced oxidation protein products; AT1, angiotensin II type 1 receptor; CCL5, C-C motif chemokine 5; CPT1, carnitine palmitoyl transferase; ERK, extracellular-regulated kinase; FAO, fatty acid oxidation; ox-LDL, oxidized LDL; MCP-1, monocyte chemoattractant protein-1; PPARα, peroxisome proliferator-activated receptor α; PPARGC1α, PPARγ co-activator 1α; RAS, renin-angiotensin system; ROS, reactive oxygen species; TNF, tumour necrosis factor.
in the heart causes cardiac hypertrophy and death 165 , whereas inhib ition of CPT1 in the liver leads to steatosis 166 . These findings suggest that CPT1 control of FAO has profound implications for cellular energy balance. In the kidney, too little CPT1 expression accompanied by decreases in the levels of other enzymes with roles in FAO might lead to an energetic crisis and potentially result in tubulo interstitial fibrosis.
The role of CD36 in FAO seems to be linked to inter-regulation of CD36 and AMPK. In the heart, AMPK functions as an important energy sensor and metabolic regulator that is activated in response to increasing energy demand and upregulates nutrient uptake, and catabolism 167 . AMPK enhances FAO by reducing the levels of malonyl-CoA via phosphorylation and inactivation of acetyl-CoA carboxylase 168 . In cardiac myocytes, CD36 coordinates dynamic protein interactions within a molecular complex consisting of CD36, Fyn kinase, LKB1 and AMPK 36 . In the setting of low fatty acid concentrations, CD36 expression maintains AMPK in a quiescent state by enabling Fyn to access and phosphorylate LKB1, thereby promoting nuclear sequestration of LKB1 away from AMPK and resulting in inhibition of AMPK and consequently of AMPK-mediated FAO 36 . However, high levels of palmitate binding to CD36 activates AMPK within minutes via its ability to dissociate Fyn from the complex following CD36 internalization into LKB1-rich vesicles 36 . The ensuing enrichment in cytosolic LKB1 levels activates AMPK, which enhances FAO by inactivating acetylCoA carboxylase 36 . AMPK activation also induces cell surface CD36 recruitment in myocytes 169 . This dual effect would serve to adjust the capacity for FAO to match fatty acid availability and balance energy saving against usage 170 . Dysregulation of AMPK signalling 171 or CD36 deletion in myocytes 172 is associated with metabolic inflexibility evidenced by a diminished capacity to adjust FAO to fatty acid availability. Whether these mechanisms also occur in the proximal tubule during kidney disease is unknown. However, targeted deletion of LKB1 in distal tubular cells resulted in a significant reduction in the levels of key effectors of FAO, such as AMPK, PGC-1α, and PPARα, and the development of renal fibrosis 173 . Moreover, Susztak and colleagues demonstrated that free palmitic acid leads to CD36-dependent proximal tubule apoptosis via activation of the p38 MAPK pathway 10 . These results could suggest that the CD36-LKB1 pathways are important in promoting metabolic dysfunction in tubular cells during CKD.
Soluble CD36 as a potential biomarker
Evidence suggests that sCD36 might have a role in modulating the immune response by binding to TLR2 (REF. 77 ). The levels of sCD36 correlate with tissue CD36 expression 174 and use of HMG-CoA reductase inhibitors (statins) has been reported to affect sCD36 levels by unknown mechanisms 175 . Several studies have suggested that sCD36 might be a valuable biomarker of disease activity in several chronic inflammatory diseases, including diabetes, non-alcoholic steatohepatitis and atherosclerosis [176] [177] [178] [179] [180] . In some clinical studies, serum levels of sCD36 positively and significantly correlated with body weight, BMI, waist circumference, monocyte counts and the levels of cholesterol and LDL 181, 182 . In patients with stage 5 CKD on dialysis (n = 228), serum sCD36 levels were significantly increased and predicted cardio vascu lar mortality 175 . Several studies have analysed sCD36 levels in plasma samples; however, these samples have the potential to skew interpretation of the results owing to the presence of CD36 in platelets, which could represent a marker of platelet activation 176, 183, 184 . Furthermore, microparticles that are released upon platelet activation might represent an important source of sCD36 80 . The available evidence indicates a close relationship between CD36 and kidney disease progression. However, the various commercial assays for sCD36 provide inconsistent results 185 . Further studies are Fully modified CD36 translocates to the plasma membrane, where it exists as monomers or dimers, and mediates fatty acid uptake, oxidative stress and inflammatory responses by triggering inflammatory signalling (not shown). Post-translational modifications may promote dimerization of CD36. Increased uptake of fatty acids results in fatty acid overload, which leads to defects in mitochondrial respiration in proximal tubule cells with reduced fatty acid oxidation (FAO) and increased intracellular lipid deposition, resulting in renal fibrosis. Metabolic defects in FAO might be restored by activating mitochondrial CD36, which enhances FAO. needed with standardized and appropriate methods to validate the use of sCD36 as a biomarker in diabetes and CKD.
CD36 as a potential therapeutic target CKD is a global health problem with no therapeutic options beyond use of renin-angiotensin system inhibitors to slow its relentless progression 186, 187 . The multiligand potential and multifunctionality of CD36 make it an attractive target to block kidney injury and subsequent progressive loss of kidney function. Several studies have demonstrated that blockade or deficiency of CD36 can block fibrosis pathways, metabolic dysfunction and proteinuria 41, 147, 122, 125 . CD36 blockade CD36-deficient mice develop low-grade proteinuria owing to loss of CD36-mediated uptake of albumin and other proteins in their proximal tubules 188 . Furthermore, silencing or antibody blockade of CD36 in PTECs exposed to AOPPs in vitro blocked the production of TGF-β 22 , which has a role in renal fibrosis, suggesting that CD36 is an important mediator of proteinuric injury. CD36 is upregulated in podocytes during proteinuric injury, and blockade of CD36 on podocytes in vitro led to an improvement in cell function with reduced apoptosis and oxidative stress 12, 22, 138, 135, 189 . Blockade of CD36-dependent pathways, therefore, holds great promise as a therapeutic strategy for a variety of kidney diseases.
Apolipoproteins are important for the formation of protein-lipid complexes and have a key role in transporting otherwise insoluble lipids within the body. A common feature of apolipoproteins is the presence of tandem 22-mer repeating domains in exon 4 (REF. 190 ). When these sequences are folded into an α-helix, they produce a structure with opposing polar and nonpolar faces 191 . Synthetic amphipathic helical peptides (SAHPs) are able to replicate structural motifs of apolipoproteins that are also able to modulate interactions with scavenger receptors such as CD36 (REFS 28, 192) .
In a mouse model of 5/6 nephrectomy with continuous angiotensin II infusion, treatment with the SAHP 5A resulted in preservation of kidney function with reduced glomerulosclerosis, interstitial fibrosis, and albuminuria compared to controls 41 . Although the 5A peptide affects other scavenger receptors (SR-Bl/ll) in addition to CD36, no benefit of 5A administration in the injury model was seen in CD36-deficient mice, suggesting a dominant role of CD36 in disease progression 41 . SAHPs with more targeted activity against CD36 (ELK-SAHPs) have also been developed. Of these, ELK-B has been shown to inhibit pulmonary inflammation and dysfunction in a sepsis model 193 . Although blockade of CD36-dependent pathways in the kidney and lung might be beneficial, the effect of this blockade on other tissues that express CD36 remains unclear.
Cyclic azopeptides are another class of peptidomimetic therapeutics that can be used to target CD36 (REF. 194 ). The azapeptide EP80317 targets the residues Gln155-Lys183 and has shown impressive efficacy in reducing disease and altering pathogenic mechanisms in experimental models of atherosclerosis and myocardial infarction 31, 195 . The efficacy of EP80317 in kidney injury is currently under investigation.
Activating mitochondrial CD36
Evidence suggests that fully modified CD36 translocates to the cytoplasmic membrane and mediates fatty acid uptake and inflammatory responses 81, 196 . In proximal tubular cells, increased levels of fatty acids lead to defects in mitochondrial respiration, reduced FAO and intracellular lipid deposition, causing renal fibrosis 40, 163, 197 . Thus, activation of mitochondrial CD36, which enhances FAO, might restore these metabolic defects (FIG. 3) . Inhibition of CD36 protein modifications by genetic or pharmacologic approaches could potentially result in increased levels of mitochondrial CD36 and, therefore, increased shuttling of fatty acids towards oxidation, which might switch fatty acids from an accumulation to a consumption phenotype and protect against kidney fibrosis.
Conclusions
CD36 has important roles in lipid homeostasis, metabolic inflammation, reprogramming of energy metabolism, apoptosis and kidney fibrosis. The expression and intracellular location of CD36 is regulated by its multiple ligands in transcription and post-translational modifications. Crosstalk between CD36 ligands, binding partners and signalling pathways, and between macrophages and kidney cells, leads to inflammation, apoptosis and/or energy reprogramming. These effects represent important molecular mechanisms for the development of CKD that warrant further investigation.
In addition, CD36 is a promising therapeutic target for kidney disease, and novel CD36-targeting peptides have shown efficacy in slowing the progression of CKD. Given the ubiquitous expression and cell-specific effects of CD36, future efforts should involve the development of novel peptides that target specific sites on the receptor and/or select cell populations to limit the potential for off-target effects and improve the efficacy of targeting CD36 in various kidney diseases. 
